Immunome, Inc.
NASDAQ:IMNMBiotechnology
Healthcare
$16.61 -2.26%
-$0.42 today
- Market cap
- $1.96B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
52W Low $7.96High $27.65
Volume 0.88M
Average 1.23M
Income Statement
Follow revenue through to earnings.
Revenue
$6.94M
FY 2025 · Annual
-23.2% YoYOperating Income
-$214.11M
FY 2025 · Annual
Net Income
-$212.39M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| 11.54M | 12.13M | 19.84M | 58.64M | 87.35M | |
| 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
IMNM Earnings Waterfall · TTM
NASDAQ:IMNM · Revenue to Net Income
Key Ratios
EPS$-2.65
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$282.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.65, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 |
How much revenue does IMNM generate?
Immunome, Inc. (IMNM) reported $6.94M of revenue in fiscal 2025.
Is IMNM profitable?
Immunome, Inc. (IMNM) reported -$212.39M of net income, with a net margin of -3060.0%.
Continue the stock analysis
Jump to another research area for this company.